Palisade Bio (PALI) Other Non Operating Income (2010 - 2026)
Palisade Bio (PALI) reported Other Non Operating Income of $1.1 million for Q1 2026, up 1318.52% year-over-year from $81000.0 in Q1 2025, and up 6.0% on a QoQ basis from $1.1 million in Q4 2025.
Palisade Bio (PALI) has 16 years of Other Non Operating Income data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Other Non Operating Income rose 1318.52% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 541.14% YoY) and the FY2025 annual result came in at $1.3 million, up 196.77% from the prior year.
- Other Non Operating Income improved to $1.1 million in Q1 2026 per PALI's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.2 million in Q2 2022 and bottomed at $41000.0 in Q4 2024.
- The 5-year median for Other Non Operating Income is $187000.0 (2023), against an average of $366823.5.
- The widest annual swing landed in 2022, when Other Non Operating Income slumped 96.66%; it then surged 2543.9% in 2025.
- Tracing PALI's Other Non Operating Income over 5 years: stood at $131000.0 in 2022, then soared by 42.75% to $187000.0 in 2023, then sank by 78.07% to $41000.0 in 2024, then surged by 2543.9% to $1.1 million in 2025, then gained by 6.0% to $1.1 million in 2026.
- Per Business Quant, the three latest PALI Other Non Operating Income figures stand at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $59000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 112,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Mar 31, 2024 | 147,000.00 |
| Dec 31, 2023 | 187,000.00 |
| Sep 30, 2023 | 190,000.00 |
| Jun 30, 2023 | 219,000.00 |
| Mar 31, 2023 | 189,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Sep 30, 2022 | 426,000.00 |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 794,000.00 |
| Sep 30, 2021 | 12.76 Mn |
| Jun 30, 2021 | 5.13 Mn |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Mar 31, 2020 | 24,625.00 |
| Dec 31, 2019 | 781,509.00 |
| Sep 30, 2019 | 26,935.00 |
| Jun 30, 2019 | 436,126.00 |
| Mar 31, 2019 | -340,115.00 |
| Dec 31, 2018 | 1.46 Mn |
| Sep 30, 2018 | 236,270.00 |
| Jun 30, 2018 | -1,646.00 |
| Mar 31, 2018 | 190,219.00 |
| Dec 31, 2017 | -1.07 Mn |
| Sep 30, 2017 | 2.68 Mn |
| Jun 30, 2017 | -341,611.00 |
| Mar 31, 2017 | -2.74 Mn |
| Dec 31, 2016 | 441,239.00 |
| Sep 30, 2016 | -538,261.00 |
| Jun 30, 2016 | 757,275.00 |
| Mar 31, 2016 | 3,199.00 |
| Dec 31, 2015 | 9,610.00 |
| Jun 30, 2015 | -10,326.00 |
| Dec 31, 2014 | -250,000.00 |
| Jun 30, 2014 | 250,000.00 |
| Mar 31, 2013 | 6,518.00 |
| Mar 31, 2011 | 161,809.00 |
| Dec 31, 2010 | 684,193.00 |
| Sep 30, 2010 | -23,535.00 |
| Jun 30, 2010 | -764,440.00 |